Clinical-stage company ImmunogenX has acquired the assets of Alvine Pharmaceuticals, which develops biologics to target autoimmune / inflammatory diseases.

The acquisition includes Latiglutenase, an orally administered mixture of two recombinant gluten-specific proteases including glutamine-specific cysteine protease (EP-B2) and a proline-specific prolyl endopeptidase (PEP) to treat celiac disease.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Alvine’s initial focus targets celiac disease, a gluten-induced autoimmune disease that currently has no drug therapy available.

Latiglutenase, formerly known as ALV003 and renamed to IMGX-003, has more than 50 issued or pending patents. It is claimed to degrade gluten proteins into small physiologically irrelevant fragments.

"ImmungenX has impressed us with their exceptional team, their drive, and most of all their dedication to helping the celiac community."

It is said to be the only CD treatment to show symptomatic improvements in clinical trials.

See Also:

Alvine Pharmaceuticals CFO and acting CEO David Southern said: "We are gratified that ALV003, which in randomised clinical trials appeared to be well tolerated and attenuated gluten-induced intestinal mucosal injury in well-controlled celiac patients, will be further developed by a company that is deeply knowledgeable about celiac disease and plans to take it through late-stage clinical trials.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

"ImmungenX has impressed us with their exceptional team, their drive, and most of all their dedication to helping the celiac community."

In addition to acquiring IMGX-003, ImmunogenX is developing an advanced diagnostic tool.

The company is extending and commercialising a clinical study for a metabolic marker compound that can measure the state of recovery of a celiac patient undergoing gluten-free diet treatment.